Liver Steatosis Management

Lifestyle Interventions

The American Diabetes Association and European Association for the Study of Diabetes recommend a Mediterranean dietary pattern, limiting ultra-processed foods rich in sugars and saturated fats, and avoiding sugar-sweetened beverages to manage liver steatosis 1, 3
A hypocaloric diet with 500-1000 kcal energy deficit is recommended to achieve weight loss of 500-1000g/week, according to the American Heart Association 3, 4
The American College of Gastroenterology advises avoiding fructose-containing beverages and foods, which can worsen steatosis 3
Limiting or avoiding alcohol consumption (no more than 1 drink/day for women, 2 drinks/day for men, or considering complete abstinence) is recommended by the National Institute on Alcohol Abuse and Alcoholism 2, 4
Engaging in at least 150 minutes/week of moderate-intensity or 75 minutes/week of vigorous-intensity physical activity is recommended by the World Health Organization, tailored to individual preference and ability 1, 3, 4

The American Association for the Study of Liver Diseases recommends using non-invasive tests like FIB-4 score, liver stiffness measurement (LSM), or NAFLD Fibrosis Score to identify patients at risk for advanced fibrosis 3, 4
Risk stratification categories are defined as:
- Low risk: FIB-4 <1.3, LSM <8.0 kPa, or liver biopsy fibrosis stage F0-F1, according to the European Association for the Study of the Liver 3, 4
- Intermediate risk: FIB-4 1.3-2.67, LSM 8.0-12.0 kPa 4
- High risk: FIB-4 >2.67, LSM >12.0 kPa 4
Non-invasive tests may be repeatedly used to assess fibrosis progression, but provide limited information about treatment response, as stated by the American Gastroenterological Association 1
Low-risk patients should have annual follow-up with repeated non-invasive tests, while intermediate and high-risk patients should have more frequent monitoring (every 6 months), according to the American College of Gastroenterology 4
Liver biopsy is not suited for routine monitoring due to invasiveness, but may be used in individual cases to assess treatment response, as recommended by the European Association for the Study of the Liver 1

A multidisciplinary approach is recommended to address all components of metabolic syndrome, according to the American Heart Association 1, 3, 4
Optimizing management of diabetes, dyslipidemia, and hypertension is crucial, as stated by the American Diabetes Association 2, 4
Considering incretin-based weight loss drugs (e.g., semaglutide, tirzepatide) for patients with type 2 diabetes or obesity is recommended by the European Association for the Study of Diabetes 1, 5
Statins are safe and effective for managing dyslipidemia in patients with fatty liver disease, according to the American College of Cardiology 4
Discontinuing medications that may worsen steatosis, such as corticosteroids, amiodarone, methotrexate, tamoxifen, estrogens, tetracyclines, and valproic acid, is advised by the National Institute of Diabetes and Digestive and Kidney Diseases 2, 4

Considering bariatric procedures for patients with class II or III obesity who have not achieved adequate weight loss through lifestyle modifications is recommended by the American Society for Metabolic and Bariatric Surgery 1, 5
Bariatric surgery is an option for individuals with liver steatosis and obesity, according to the International Federation for the Surgery of Obesity and Metabolic Disorders 5

For patients with advanced disease, considering referral to hepatology for specialized management and potential pharmacotherapy is recommended by the American Association for the Study of Liver Diseases 5, 4
Patients with cirrhosis require surveillance for portal hypertension and hepatocellular carcinoma, as stated by the European Association for the Study of the Liver 5, 2